TFF Pharmaceuticals has partnered with CDMO Catalent for scale-up and manufacturing of dry powder formulations based on TFF’s thin film freezing technology the companies have announced. The partnership will make the TFF technology available to other Catalent clients as well. Catalent notes that the TFF technology is its second addition to its inhaled dry powder manufacturing capabilities since the beginning of 2021 when the company acquired the former Acorda Therapeutics spray drying facility in Massachusetts.
Catalent President, Oral and Specialty Delivery, Jonathan Arnold said, “Catalent is pleased to leverage its extensive expertise in the development and CGMP manufacture of dry powders in order to potentially bring TFF Pharmaceuticals’ unique and differentiated technology to scale.”
TFF Pharmaceuticals CEO Glenn Mattes commented, “Catalent is widely known as a global leader in enabling pharmaceutical development and manufacturing and has distinguished itself by demonstrating cutting-edge expertise across multiple modalities and innovative projects. We are therefore delighted to significantly expand our collaboration with the Catalent team. This strategic collaboration significantly expands our access to manufacturing capabilities and provides scalability for our technology, while simultaneously affording us the opportunity to build our portfolio of technology licensing partnerships.”
TFF’s pipeline includes inhaled formulations of niclosamide for COVID-19; Aug-3387 mAb for COVID-19; voriconazole for IPA; and tacrolimus for prevention of organ transplant rejection. The company is also working with the US army on inhaled dry powder vaccines and has reported success in using its technology to formulate an inhaled mAb against Ebola and a vaccine against equine encephalitis.
Read the Catalent and TFF Pharmaceuticals press release.
